Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
This was the stock's third consecutive day of gains.
Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work ...
Shares of Vertex Pharmaceuticals Inc. VRTX slid 0.46% to $408.76 Friday, on what proved to be an all-around rough trading ...
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 ...
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.
We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are ...
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...